AbbVie’s Skyrizi scoops up CHMP recommendation for moderate to severe plaque psoriasis
March 4, 2019Sales and Marketing AbbVie, pharma, psoriasis
AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), …
Indian government set to colour code generic medicines
March 4, 2019Sales and Marketing India, Indian health, costs, generic medicines, pricing, sales
As part of an effort to promote low cost medicines, the Indian government has announced plans to colour code generic …
Doctors call on Canadian government to stop funding programme sending homeopaths to Honduras
March 4, 2019Sales and Marketing Canada, Hodnuras, Quebec, TSF, health, homeopathy
Canadian physicians have called on the federal government to review its funding for a programme which sends volunteer homeopaths to …
Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar
March 4, 2019Sales and Marketing Biogen, Nightstar, acquisition, pharma
Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of …
NHS chief warns of rise of anti-vaccine ‘fake news’ online
March 4, 2019Sales and Marketing NHS, NHS England, Simon Stevens, anti vaxxer, fake news, vaccines
The head of NHS England has warned that ‘vaccination deniers’ are increasing their influence on social media through ’fake news’. …
Top Ten most popular articles on Pharmafile.com this week!
March 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, GP, Michael Cohen, Novartis, Roche, Sanofi, Senate, UK, crispr, top 10
As the CRISPR twins’ story unfolds, scientists revealed that the Chinese babies were likely altered in a way that improves …
Bernie Sanders calls on FDA to allow generic, low cost versions of Catalyst Pharma’s $375,000 rare disease drug
March 1, 2019Medical Communications Bernie Sanders, Catalyst Pharmaceuticals Jacobus
US Senator Bernie Sanders has called on regulators to allow pharmacies and manufacturers to distribute generic versions of Catalyst Pharmaceuticals’ …
J&J sign deal with Scottish firm AdoRx to develop novel lung cancer treatments
March 1, 2019Medical Communications AdoRx, Cancer, Cancer Immunotherapy, J&J, JJ, immunology, oncology
Edinburgh-based drug discovery firm AdoRx therapeutics has signed a deal with US healthcare conglomerate Johnson & Johnson to develop novel …
Philippines Department of Justice recommends charges against six Sanofi officials
March 1, 2019Medical Communications Philippines, Sanofi, dengue, dengvaxia, vaccines
The Philippine Justice Ministry has said it has found probably cause to charge officials working for French drugmaker Sanofi over …
Nearly half of childhood cancer cases go untreated and undiagnosed
March 1, 2019Medical Communications Cancer, childhood cancer, diagnosis, oncology, pediatric, world
Almost half of all children with cancer are going untreated and undiagnosed, according to research published in Lancet Oncology. While …
Working Life: Nicola Redfern, UK General Manager, bluebird bio
February 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bluebird Bio, Interview, Working Life, pharma
How did you find your way into the pharma industry? Was it always an aspiration of yours? My mum worked …
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
February 28, 2019Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, …
More than 40% of GPs intend to quit within five years
February 28, 2019Medical Communications GPs, NHS, NHS LOng term plan, UK, brexit, workforce
More than 40% of GPs intend to quit within five years according to researchers at the University of Warwick. The …
Trump ex-lawyer Cohen reveals Novartis pushed him to lobby
February 28, 2019Sales and Marketing Donald Trump, Michael Cohen, Novartis, US, pharma
Among the swirling storm emanating from the testimony of Donald Trump’s ex-lawyer Michael Cohen to the House Oversight Committee, one …
Scientists genetically modify yeast to produce CBD and THC
February 28, 2019Research and Development Medical marijuana, berkely, cannabis, science, yeast
Researchers at the University of California, Berkeley have genetically modified brewer’s yeast so that it produces two common cannabinoids: tetrahydrocannabinol …
Patients to recieve MDMA-assisted psychotherapy on ‘compassionate’ grounds in Israel
February 28, 2019Research and Development MDMA, PTSD, drugs, mental health, psychedelics
The Israeli Health Ministry has approved the compassionate use of MDMA-assisted psychotherapy for 50 patients with post-traumatic stress disorder (PTSD). …
Darknet sales of prescription psychiatric drugs increasing in the UK
February 27, 2019Research and Development, Sales and Marketing King's College London, Kings College London, University of Kent, darknet, pharma
Research from the University of Kent and King’s College London has revealed that UK sales of prescription psychiatric drugs, including …
Vaccine biotech Emergex name experienced pharma professional Dr Athanasios Papadopoulos as new CMO
February 27, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Emergex Vaccine Holdings Limited has named Dr Athanasios Papadopoulos as the company’s new Chief Medical Officer (CMO). The appointment, effective …
Pharma execs testify in front of Senate of rising drug prices
February 27, 2019Research and Development Business, Senate hearing, USA, pharma, sfc
Senior Executives from seven major pharmaceutical companies, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Pfizer, Sanofi and Johnson & …
Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3
February 27, 2019Research and Development Dupixent, Sanofi, pharma, rhinosinusitis
New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
